FDA accepts review of AstraZeneca drug for hyperkalaemia
The US Food and Drug Administration has accepted a complete re-submission of a new drug application for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia by AstraZeneca’s subsidiary ZS Pharma.
AstraZeneca
11,780.00p
16:45 20/09/24
-0.99%
-118.00p
FTSE 100
8,229.99
17:14 20/09/24
n/a
n/a
FTSE 350
4,543.89
16:49 20/09/24
n/a
n/a
FTSE All-Share
4,501.08
17:04 20/09/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,415.97
16:49 20/09/24
-1.31%
-296.71
Hyperkalaemia – high potassium levels in the blood serum – commonly occurs in patients with advanced chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death.
AstraZeneca said the FDA has indicated this is a complete class 2 response.
Interactions with other health authorities in the European Union and Australia are ongoing with decisions expected in the first half of 2017.